Bring us one day closer to the cure of this fatal disease to deliver.

Dr. Jakubowiak and other researchers continue to evaluate this novel study drug treatment in the ongoing Phase III ASPIRE study lenalidomide and dexamethasone with or without carfilzomib in relapsed myeloma. The U.S. Food and Drug Administration is currently evaluating carfilzomib for the treatment of relapsed and refractory myeloma. Our hope is that our findings help to an effective treatment option for patients with multiple myeloma, bring us one day closer to the cure of this fatal disease to deliver, added Dr. Jakubowiak.

New Frontline treatment regimen for multiple myelomaresults from a study published online in Blood, the journal the American Society of Hematology , that the inclusion of carfilzomib a novel targeted therapy for multiple myeloma in combination with lenalidomide and low-dose dexamethasone, resulted in a complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma.The investigators led by Carol Wise, at Scottish Rite Hospital, collected data on 52 families with a story of scoliosis into less than two members – the one that treat and any other from earlier generations. Patients had a mean curvature of your spine from 40 degrees and do not have disease, how Marfan and cerebral, the can be and involve scoliosis. The researchers conducted genome-wide scans, which to writing the 6 billion letters of genetic code in affected analyze analyzed which dates..